ArticleJAAD international2020
Burden of skin disease and associated socioeconomic status in Europe: An ecologic study from the Global Burden of Disease Study 2017.
Article in JAAD international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Advancements and challenges of artificial intelligence in dermatology: a review of applications and perspectives in China.Frontiers in digital health · 2025Pooled it
- Prevalence and determinants of scabies: A global systematic review and meta-analysis.Tropical medicine & international health : TM & IH · 2024Pooled it
- The Burden of Urticaria in the Middle East and North Africa Region From 1990 to 2021: A Systematic Analysis Based on the GBD Study 2021.Health science reports · 2026Article
- Global, regional and national burden of skin and subcutaneous diseases: a systematic analysis of the Global Burden of Disease Study 2021.International health · 2026Article
- From Optical to Molecular Imaging on Human Skin: A Review.Chemical & biomedical imaging · 2026Review
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Long-Term PMLife (Basel, Switzerland) · 2025Review
- The Burden of Skin and Subcutaneous Diseases in North Africa and the Middle East (NAME) From 1990 to 2021.International journal of dermatology · 2025Article
- Skin-on-chip: Quo vadis?APL bioengineering · 2025Review
- A drug delivery perspective on nanotechnology-based topical therapeutics for inflammatory skin diseases.Nanomedicine (London, England) · 2025Review
- Role of Polyphenols in Dermatological Diseases: Exploring Pharmacotherapeutic Mechanisms and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Global burden of skin and subcutaneous diseases and its association with socioeconomic status in children and adolescents: an analysis of the Global Burden of Diseases Study 2019.Archives of dermatological research · 2024Article
- Article
- Teledermatology to Improve Access to and Quality of Skin Care in Eastern Indonesia.The American journal of tropical medicine and hygiene · 2024Article
- Article
- Burden of Skin and Subcutaneous Diseases in Indonesia 1990 to 2019.Acta dermato-venereologica · 2023Article
- The burden of skin and subcutaneous diseases: findings from the global burden of disease study 2019.Frontiers in public health · 2023Article
- Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years.BMC cancer · 2022Article
- Skin-on-a-Chip Technology: Microengineering Physiologically Relevant In Vitro Skin Models.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDermatoses contribute to a large burden of global disease, but the relationship between socioeconomic status and the effect of dermatologic conditions in Europe is not well understood.
methodsWe selected Global Burden of Disease Study data sets to analyze disability-adjusted life-years (DALYs) and the annual rate of change of dermatoses between 1990 and 2017 in 43 European countries. The principal country-level economic factor used was gross domestic product per capita from the World Bank. Statistical analysis was performed with Spearman ρ correlation.
resultsWealthier European countries had higher DALYs for melanoma, basal cell carcinoma, psoriasis, atopic dermatitis, acne, seborrheic dermatitis, alopecia, asthma, contact dermatitis, and viral skin disease. Poorer countries had higher DALYs of squamous cell carcinoma, urticaria, decubitus ulcers, pruritus, scabies, tuberculosis, and syphilis. Thirteen European countries were in the top 10th percentile globally for annual increase in skin and subcutaneous disease burden.
conclusionThe majority of European countries have experienced an increase in skin and subcutaneous diseases in recent decades relative to the rest of the world, but the burden of individual dermatoses in Europe varies by country and socioeconomic status. DALYs can potentially serve as a purposeful measure for directing resources to improve the burden of skin disease in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.